SG11202105163UA - Agent for inhibiting iron uptake into cells - Google Patents

Agent for inhibiting iron uptake into cells

Info

Publication number
SG11202105163UA
SG11202105163UA SG11202105163UA SG11202105163UA SG11202105163UA SG 11202105163U A SG11202105163U A SG 11202105163UA SG 11202105163U A SG11202105163U A SG 11202105163UA SG 11202105163U A SG11202105163U A SG 11202105163UA SG 11202105163U A SG11202105163U A SG 11202105163UA
Authority
SG
Singapore
Prior art keywords
cells
agent
iron uptake
inhibiting iron
inhibiting
Prior art date
Application number
SG11202105163UA
Other languages
English (en)
Inventor
Lilin Zhang
Fumiko Nomura
Keiko Katsumi
Romi KOTAKA
Yuta OHIRA
Original Assignee
Perseus Proteomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perseus Proteomics Inc filed Critical Perseus Proteomics Inc
Publication of SG11202105163UA publication Critical patent/SG11202105163UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
SG11202105163UA 2018-11-20 2019-11-19 Agent for inhibiting iron uptake into cells SG11202105163UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018217548 2018-11-20
JP2019167013 2019-09-13
PCT/JP2019/045227 WO2020105621A1 (ja) 2018-11-20 2019-11-19 細胞内への鉄の取り込み阻害剤

Publications (1)

Publication Number Publication Date
SG11202105163UA true SG11202105163UA (en) 2021-06-29

Family

ID=70774551

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105163UA SG11202105163UA (en) 2018-11-20 2019-11-19 Agent for inhibiting iron uptake into cells

Country Status (12)

Country Link
US (1) US20220332838A1 (ja)
EP (1) EP3884959A4 (ja)
JP (1) JP7410051B2 (ja)
KR (1) KR20210093974A (ja)
CN (1) CN113164594A (ja)
AU (1) AU2019384781A1 (ja)
BR (1) BR112021009768A2 (ja)
CA (1) CA3120548A1 (ja)
MX (1) MX2021005913A (ja)
SG (1) SG11202105163UA (ja)
WO (1) WO2020105621A1 (ja)
ZA (1) ZA202103554B (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022075439A1 (ja) 2020-10-08 2022-04-14 国立大学法人東海国立大学機構 抗トランスフェリンレセプター抗体の薬効又は感受性の判定方法
CN117836003A (zh) 2021-08-26 2024-04-05 株式会社英仙蛋白质科学 Ros（活性氧类）产生增强剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
ATE208374T1 (de) 1992-02-18 2001-11-15 Otsuka Kagaku Kk Beta-laktam und cepham verbindungen und ihre herstellung
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
JP3507073B2 (ja) 1992-03-24 2004-03-15 ケンブリッジ アンティボディー テクノロジー リミティド 特異的結合対の成員の製造方法
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
PT1740616E (pt) 2004-04-30 2012-03-23 Inst Nat Sante Rech Med Anticorpo anti-rtf
CN101245107B (zh) * 2007-02-14 2010-10-13 中国人民解放军军事医学科学院生物工程研究所 抗人转铁蛋白受体人源抗体及其应用
JP2012532925A (ja) * 2009-07-16 2012-12-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 癌の処置のための化合物および方法
US9598496B2 (en) * 2011-05-09 2017-03-21 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
JP5939855B2 (ja) 2012-03-23 2016-06-22 国立大学法人 宮崎大学 トランスフェリン受容体抗体
JP2015524816A (ja) 2012-08-02 2015-08-27 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル サラセミアを処置するためのトランスフェリンレセプターアンタゴニストの使用
CN104797600A (zh) * 2012-11-08 2015-07-22 国立大学法人宫崎大学 能够特异性识别转铁蛋白受体的抗体
JP2014093958A (ja) * 2012-11-08 2014-05-22 Univ Of Miyazaki トランスフェリン受容体を特異的に認識できる抗体
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
CN114409783A (zh) * 2015-06-24 2022-04-29 Jcr制药股份有限公司 通过血脑屏障的抗人转铁蛋白受体抗体
JP2018024615A (ja) * 2016-08-10 2018-02-15 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−１関連炎症性疾患を治療する医薬組成物

Also Published As

Publication number Publication date
EP3884959A4 (en) 2022-08-10
MX2021005913A (es) 2021-06-30
ZA202103554B (en) 2023-01-25
EP3884959A1 (en) 2021-09-29
CA3120548A1 (en) 2020-05-28
CN113164594A (zh) 2021-07-23
JPWO2020105621A1 (ja) 2021-10-07
BR112021009768A2 (pt) 2021-10-19
WO2020105621A1 (ja) 2020-05-28
JP7410051B2 (ja) 2024-01-09
AU2019384781A1 (en) 2021-06-10
KR20210093974A (ko) 2021-07-28
US20220332838A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
IL275263A (en) Preparations and methods for inhibiting T cell exhaustion
IL272643A (en) Binders
GB201802201D0 (en) Binding agents
IL272838B1 (en) Peptidase-specific ubiquitin inhibition 30
SG10202004443YA (en) Pre-coated shield for use in vhf-rf pvd chambers
ZA202001283B (en) Iron complex compounds for therapeutic use
PL3765646T3 (pl) Kompozycja stali
IL268288A (en) Binders
ZA202103554B (en) Agent for inhibiting iron uptake into cells
GB201706116D0 (en) Iron ore pellets
ZA202110908B (en) Improved fertiliser
SG10201912979UA (en) Composition for inhibiting carnosine dipeptidase
GB2541102B (en) Extension piece for drain hoppers
IL276914A (en) CSF1R binding factors
GB201913756D0 (en) Contrast agent
GB201711208D0 (en) Ion channel inhibitors
EP4071294C0 (en) CORD WINDING IRON
IL279709A (en) ASK1 inhibitory agents
EP4053295A4 (en) LEATHER IMPROVEMENT AGENTS
GB201808716D0 (en) Briquettes
IL291366A (en) A radiolabeled grpr antagonist for use as a therapeutic
ZA202103578B (en) Dna-cutting agent
ZA202103582B (en) Dna-cutting agent
RS62891B1 (sr) Kompozicija za lečenje konstipacije
ZA201905047B (en) Briquettes